Bajaj HealthCare
394.15
+8.95(+2.32%)
Market Cap₹1,244.85 Cr
PE Ratio26.65
IndustryHealthcare
Company Performance:
1D+2.32%
1M-4.56%
6M-17.64%
1Y-25.12%
5Y+8.60%
View Company Insightsright
More news about Bajaj HealthCare
17Oct 25
Bajaj Healthcare Reports Q2 FY26 Revenue of ₹1,470.49 Crore, PAT at ₹1,110.92 Crore
Bajaj Healthcare Limited announced strong Q2 FY26 results with revenue from operations increasing 13.04% YoY to ₹1,470.49 crore. Profit After Tax rose 17.37% to ₹1,110.92 crore. For H1 FY26, revenue surged 44.50% to ₹2,967.51 crore, with PAT up 38.24% to ₹2,294.29 crore. The company's EPS for Q2 FY26 improved to ₹3.53. Bajaj Healthcare also reported acquiring Genrx Pharmaceuticals Private Limited for ₹1,085 lakhs in April 2025.
04Oct 25
Bajaj Healthcare Secures Approval for Phase III Trials of Insomnia Drug Suvorexant
Bajaj Healthcare Limited (BHL) has received approval from the Subject Expert Committee of CDSCO to conduct Phase III clinical trials for Suvorexant Tablets in India. Suvorexant, a prescription medication for treating insomnia in adults, will be tested in 5 mg, 10 mg, 15 mg, and 20 mg strengths. BHL is the first company in India to receive this regulatory clearance for Suvorexant. The trials aim to assess the drug's efficacy, safety, and tolerability before seeking marketing authorization. BHL shares closed at ₹482.60, up 0.62% following the news.
11Sept 25
Bajaj Healthcare Announces Record Date for Final Dividend of FY 2024-25
Bajaj Healthcare Limited has announced September 19, 2025, as the record date for the final dividend of ₹1.00 per equity share (20%) for FY 2024-25. The dividend is subject to approval at the upcoming Annual General Meeting. Shareholders holding equity shares on the record date will be eligible for the dividend payment. The announcement complies with SEBI regulations and has been communicated to the BSE and NSE.
18Aug 25
Bajaj Healthcare Appoints Sandeep Shah as Additional Non-Executive Director
Bajaj Healthcare's Board of Directors has appointed Sandeep Shah as an Additional Director in the Non-Executive Non-Independent category, effective August 18, 2025. Shah, a commerce graduate with over 23 years of experience in Registrar and Share Transfer services, has worked with organizations like Karvy Consultants Private Limited and Par Computer Sciences (International) Limited. He also has more than 16 years of experience in Company Secretarial work with a PCS firm. The appointment is subject to shareholder approval.
28Jul 25
Bajaj Healthcare Reports Strong Q1 Results, Projects Robust Growth
Bajaj Healthcare Limited reported impressive Q1 financial results with revenue from operations increasing by 12.5% year-on-year to ₹148.84 crore. The company's API export business surged by 68.4%, while the formulations segment grew by 41.1%. Profit for the period rose by 65.9% to ₹11.83 crore. The company received new regulatory approvals, advanced its CDMO operations, and made progress in pipeline development. Bajaj Healthcare's export contribution increased to 35% of total revenue, up from 23% in the same quarter last year.
28Jul 25
Bajaj Healthcare Reports 66% Surge in Q1 Net Profit Amid Revenue Growth
Bajaj Healthcare announced its Q1 FY2026 results, reporting a 66% increase in net profit to ₹118.00 crore. Revenue grew by 12.6% to ₹1,488.00 crore. However, EBITDA remained flat at ₹245.00 crore, with margins compressing to 16.47% from 18.53% year-over-year. The Board of Directors approved these unaudited standalone financial results on July 28, 2025, after a review by statutory auditors Walker Chandiok & Co. LLP.
27May 25
Bajaj Healthcare Swings to Profit in Q4, Announces Dividend
Bajaj Healthcare Ltd. reported a significant turnaround in Q4, posting a net profit of ₹111.80 crore compared to a loss of ₹299.20 crore in the previous year. Revenue increased to ₹154.00 crore, up 14.93% year-over-year. The company's board recommended a final dividend of ₹1.00 per equity share. Despite the strong yearly recovery, there was a slight decrease in profit from ₹117.20 crore in the previous quarter.
26May 25
Bajaj Healthcare Reports Q4 Profit Turnaround and Announces Dividend
Bajaj Healthcare Limited's Q4 results show a significant improvement, with revenue increasing by 14.93% to ₹154.00 crore. The company returned to profitability with a net profit of ₹11.18 crore, compared to a loss of ₹29.92 crore in the same quarter last year. Despite EBITDA declining to ₹11.76 crore and margins contracting to 7.61%, the board recommended a final dividend of ₹1.00 per equity share.
10Apr 25
Bajaj Healthcare Strengthens Financial Leadership with Appointment of Rohan Parekh as CFO
Bajaj Healthcare Limited has appointed Mr. Rohan Parekh as the new Chief Financial Officer (CFO) and Key Managerial Personnel, effective April 16, 2025. Mr. Parekh, a qualified chartered accountant with over 13 years of experience, brings expertise in corporate strategy, financial planning, and treasury management. Additionally, the company has granted 2,500 stock options to employees under its 2024 ESOP plan, with an exercise price of Rs. 5.00 per option.
08Apr 25
Bajaj Healthcare Expands with Genrx Pharmaceuticals Acquisition, Considers Bonus Shares
Bajaj Healthcare Limited has acquired Genrx Pharmaceuticals Private Limited for ₹10.85 crore in an all-cash deal, gaining 100% control. The acquisition, completed on April 4, 2025, aims to expand Bajaj Healthcare's manufacturing capabilities. Genrx Pharmaceuticals is a WHO-GMP certified manufacturer specializing in allopathic formulations, nutraceuticals, and natural products. The integration is expected to take 3-6 months, pending regulatory approvals. Additionally, Bajaj Healthcare's board will meet on April 16 to consider issuing bonus shares.
07Apr 25
Bajaj Healthcare Expands Manufacturing Capabilities with ₹10.85 Crore Acquisition of Genrx Pharmaceuticals
Bajaj Healthcare Limited (BHL) has acquired Genrx Pharmaceuticals Private Limited for ₹10.85 crore in cash, gaining 100% control. Genrx, a WHO-GMP certified manufacturer, specializes in allopathic formulations, nutraceuticals, and natural products. The acquisition expands BHL's manufacturing portfolio, strengthening its position in the pharmaceutical sector. The deal is expected to close in 3-6 months, pending regulatory approvals.
03Apr 25
Bajaj Healthcare CFO Dayashankar Patel Resigns, Effective April 15
Bajaj Healthcare Limited (BHL) announced the resignation of CFO Dayashankar Patel, effective April 15, 2025, citing personal reasons. The company appreciated his services and confirmed no material reasons for the resignation beyond those stated. The announcement complies with SEBI regulations, and BHL is expected to manage the transition in financial leadership.
02Apr 25
Bajaj Healthcare CFO Dayashankar Patel Steps Down, Citing Personal Reasons
Bajaj Healthcare Limited announced that its Chief Financial Officer (CFO), Dayashankar Patel, has resigned due to personal reasons. Patel will be relieved from his duties as CFO and Key Managerial Personnel after April 15, 2025. The company expressed appreciation for Patel's services and confirmed no material reasons for the resignation beyond those stated. The announcement was made on April 2, 2025, allowing for a brief transition period. Bajaj Healthcare has complied with SEBI regulations by disclosing the change to relevant stock exchanges. No successor has been announced yet.
Bajaj HealthCare
394.15
+8.95
(+2.32%)
1 Year Returns:-25.12%
Industry Peers
Sun Pharmaceutical
1,700.70
(-1.62%)
Divis Laboratories
6,355.50
(-1.26%)
Torrent Pharmaceuticals
4,003.70
(+1.61%)
Cipla
1,434.50
(-0.95%)
Lupin
2,195.90
(+0.78%)
Dr Reddys Laboratories
1,186.50
(-0.40%)
Mankind Pharma
2,244.40
(+1.38%)
Zydus Life Science
883.75
(-1.88%)
Alkem Laboratories
5,830.50
(-0.56%)
Aurobindo Pharma
1,180.10
(+1.06%)